



LKT Laboratories, Inc.

CH5424802

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID C2900

CAS No. 1256580-46-7

Chemical Name

Synonym CH 5424802, Alectinib

Formula $C_{30}H_{34}N_4O_2$

Formula Wt. 482.62

Melting Point


Purity $\geq 99\%$

Solubility DMSO 0.5 mg/mL warmed
(1.03 mM)
Water Insoluble
Ethanol Insoluble

Store Temp $-20^{\circ}C$

Ship Temp Ambient

Description CH5424802 is an inhibitor of anaplastic lymphoma kinase (ALK) that displays anticancer chemotherapeutic and anti-metastatic activities against WT and L1196M mutant ALK. This compound is in clinical trials as a potential treatment for various cancers. CH5424802 induces regression of non-small cell lung cancer (NSCLC) cell metastasis in the brain in vivo, increasing survival rates. This compound displays efficacy in subjects resistant to crizotinib. TEST!!!!!!



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
C2900	1 mg	\$104.80
C2900	5 mg	\$171.00
C2900	10 mg	\$266.40

References Santarpia M, Altavilla G, Rosell R. Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer. *Expert Rev Respir Med.* 2015 Feb 5:1-14. [Epub ahead of print]. PMID: 25652176.

Kodama T, Hasegawa M, Takanashi K, et al. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. *Cancer Chemother Pharmacol.* 2014 Nov;74(5):1023-8. PMID: 25205428.

Kodama T, Tsukaguchi T, Yoshida M, et al. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. *Cancer Lett.* 2014 Sep 1;351(2):215-21. PMID: 24887559.

Rossi A, Maione P, Sacco PC, et al. ALK inhibitors and advanced non-small cell lung cancer (review). *Int J Oncol.* 2014 Aug;45(2):499-508. PMID: 24889366.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.